(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 18.3% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.4%.
Alvotech's revenue in 2026 is $588,904,000.On average, 8 Wall Street analysts forecast ALVO's revenue for 2026 to be $208,149,459,263, with the lowest ALVO revenue forecast at $188,882,139,356, and the highest ALVO revenue forecast at $223,700,604,593. On average, 8 Wall Street analysts forecast ALVO's revenue for 2027 to be $246,930,595,961, with the lowest ALVO revenue forecast at $217,591,226,070, and the highest ALVO revenue forecast at $294,729,150,398.
In 2028, ALVO is forecast to generate $308,445,610,043 in revenue, with the lowest revenue forecast at $268,475,671,905 and the highest revenue forecast at $356,952,453,000.